Short answer: The US FDA’s guidance for a low-level laser system for aesthetic use is not a universal rulebook for every beauty laser. It addresses a particular Class II device type under 21 CFR 878.5400, product code OLI. Buyers should first confirm the exact intended use and model, then ask for the evidence and labeling relevant to that classification. The guidance was issued in 2011; it is background for a present-day procurement decision, not new 2026 regulatory news.
Why a narrow scope matters
FDA identifies this generic type as a device using low-level laser energy to disrupt adipocyte cells in the fat layer and release fat and lipids for non-invasive aesthetic use. That description is much more specific than the phrase “aesthetic laser.” It should not be pasted onto an IPL hair-removal platform, a laser for skin resurfacing or an LED mask because those products may differ in energy, intended use, classification and evidence. A seller who offers a broad portfolio should document the regulatory basis for each configuration rather than present one guidance document as a portfolio-wide certificate.
For the device type within scope, FDA says manufacturers must address general controls, the specific risks identified in the guidance and the applicable premarket notification requirements, and obtain a substantial-equivalence determination before marketing. The guidance discusses components, software, accessories, bench testing, software validation, clinical testing where appropriate, biocompatibility, electromagnetic compatibility, electrical and mechanical safety, and labeling. Its recommendations can be met through the described approach or another approach that provides equivalent assurances. That flexibility should not be confused with an exemption from documenting safety and effectiveness.
A buyer’s evidence request
Ask for the marketed model name, manufacturer, product code, exact indications for use and a traceable FDA decision reference if the supplier claims clearance. Compare the offered unit with the device and accessories in that record. Request the user manual, contraindications, warnings, maintenance schedule, operator training and service process. Record who will be responsible for accepting and inspecting the unit on delivery and what happens if the delivered configuration differs from the quotation. Those questions reveal more than a generic badge on a brochure.
For a proposed body-contouring service, an operator also needs clinical and business review of what the evidence actually supports. A measurement in one study, a temporary appearance change or a specific indicated use cannot justify a broader promise of permanent fat loss or guaranteed individual outcomes. Advertising and consent language should be checked against the precise evidence package. The FDA guidance is addressed primarily to manufacturers preparing a submission; it does not replace clinical judgment or state rules governing who may operate a device.
What this does not establish
The page does not identify a TUOKE laser, describe its performance or say that TUOKE holds US authorization. Nor does it establish that all low-energy light products are Class II OLI devices. Buyers should verify current FDA records and seek qualified regulatory advice on the actual intended use. In a mixed laser, IPL and LED catalogue, the first disciplined step is to separate technologies and claims rather than assume a shared approval pathway.
Explore further due-diligence topics in the optical aesthetic equipment insights archive.
Source
- US FDA, Low Level Laser System for Aesthetic Use: Class II Special Controls Guidance, issued April 14, 2011; reviewed October 13, 2026.